These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20620435)

  • 1. Biology and chemistry of thrombopoietic agents.
    Kuter DJ
    Semin Hematol; 2010 Jul; 47(3):243-8. PubMed ID: 20620435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
    Newland A
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New thrombopoietic growth factors.
    Kuter DJ
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S347-56. PubMed ID: 19778863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romiplostim: a second-generation thrombopoietin agonist.
    Cohn CS; Bussel JB
    Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
    Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
    Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study.
    Sheng XY; Liu ZY; Zhao J; Song L; Zhao WM; Zhao X; Cui YM
    Platelets; 2022 Nov; 33(8):1185-1191. PubMed ID: 35549802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
    Kuter DJ
    Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R; Evangelista ML; Amadori S
    Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of thrombopoietin and thrombopoietin receptor agonists.
    Kuter DJ
    Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic immune thrombocytopenic purpura. New agents.
    Rodeghiero F; Ruggeri M
    Hamostaseologie; 2009 Jan; 29(1):76-9. PubMed ID: 19151853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
    Shinohara K; Kambara N
    Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.
    Tiu RV; Sekeres MA
    Expert Opin Biol Ther; 2008 Jul; 8(7):1021-30. PubMed ID: 18549331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Romiplostim Mechanism of Action and Clinical Applicability.
    Bussel JB; Soff G; Balduzzi A; Cooper N; Lawrence T; Semple JW
    Drug Des Devel Ther; 2021; 15():2243-2268. PubMed ID: 34079225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM
    Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.